Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Chem ; 67(9): 7112-7129, 2024 May 09.
Article in English | MEDLINE | ID: mdl-38647397

ABSTRACT

Research into kappa opioid receptor (KOR) agonists with attenuated central-nervous-system side effects is a critical focus for developing productive and safe analgesics. Herein, a series of ortho-substituted N-cyclopropylmethyl-7α-phenyl-6,14-endoethano-tetrahydronorthebaines were designed, synthesized, and subjected to bioassays. Compound 7a exhibited high subtype selectivity and potent agonistic activity toward KOR (KOR, Ki = 3.9 nM, MOR/KOR = 270, DOR/KOR = 1075; [35S]GTPγS binding, EC50 = 3.4 nM). Additionally, this compound exhibited robust and persistent antinociceptive effects in rodent models with different animal strains (hot plate test, ED50 = 0.20-0.30 mg/kg, i.p.; abdominal constriction test, ED50 = 0.20-0.60 mg/kg, i.p.), with its KOR-mediated mechanism for antinociception firmly established. Notably, compound 7a, unlike conventional KOR agonists, displayed minimal sedation and aversion at the antinociceptive ED50 dose. This feature addresses a crucial limitation in existing KOR agonists, positioning compound 7a as a promising novel therapeutic agent.


Subject(s)
Receptors, Opioid, kappa , Receptors, Opioid, kappa/agonists , Receptors, Opioid, kappa/metabolism , Animals , Mice , Structure-Activity Relationship , Male , Humans , Hypnotics and Sedatives/pharmacology , Hypnotics and Sedatives/chemical synthesis , Hypnotics and Sedatives/chemistry , Rats , Analgesics/pharmacology , Analgesics/chemical synthesis , Analgesics/chemistry , Drug Discovery , Rats, Sprague-Dawley , Cricetulus
2.
J Med Chem ; 62(24): 11054-11070, 2019 12 26.
Article in English | MEDLINE | ID: mdl-31738550

ABSTRACT

Effective and safe analgesics represent an unmet medical need for the treatment of acute and chronic pain. A series of N-cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines were designed, synthesized, and assayed, leading to the discovery of a benzylamine derivative (compound 4, SLL-039) as a highly selective and potent κ opioid agonist (κ, Ki = 0.47 nM, κ/µ = 682, κ/δ = 283), which was confirmed by functional assays in vitro and antinociceptive assays in vivo. The in vivo effect could be blocked by pretreatment with the selective κ antagonist nor-BNI. Moreover, this compound did not induce sedation, a common dose limiting effect of κ opioid receptor agonists, at its analgesic dose compared to U50,488H. The dissociation of sedation/antinociception found in SLL-039 was assumed to be correlated with the occupation of its benzamide motif in a unique subsite involving V1182.63, W124EL1, and E209EL2.


Subject(s)
Analgesics, Opioid/pharmacology , Analgesics/pharmacology , Benzylamines/pharmacology , Central Nervous System/drug effects , Drug Discovery , Morphinans/pharmacology , Pain/drug therapy , Receptors, Opioid, kappa/agonists , Analgesics/chemistry , Analgesics, Opioid/chemistry , Animals , Behavior, Animal/drug effects , Benzamides/chemistry , Benzylamines/chemistry , Dose-Response Relationship, Drug , Locomotion/drug effects , Male , Mice , Morphinans/chemistry , Pain/metabolism
3.
Sci Rep ; 8(1): 14087, 2018 09 20.
Article in English | MEDLINE | ID: mdl-30237513

ABSTRACT

Dezocine is becoming dominated in China market for relieving moderate to severe pain. It is believed that Dezocine's clinical efficacy and little chance to provoke adverse events during the therapeutic process are mainly attributed to its partial agonist activity at the µ opioid receptor. In the present work, we comprehensively studied the pharmacological characterization of Dezocine and identified that the analgesic effect of Dezocine was a result of action at both the κ and µ opioid receptors. We firstly found that Dezocine displayed preferential binding to µ opioid receptor over κ and δ opioid receptors. Dezocine, on its own, weakly stimulated G protein activation in cells expressing κ and µ receptors, but in the presence of full κ agonist U50,488 H and µ agonist DAMGO, Dezocine inhibited U50,488H- and DAMGO-mediated G protein activation, indicating that Dezocine was a κ partial agonist and µ partial agonist. Then the in intro results were verified by in vivo studies in mice. We observed that Dezocine-produced antinociception was significantly inhibited by κ antagonist nor-BNI and µ antagonist ß-FNA pretreatment, indicating that Dezocine-mediated antinociception was via both the κ and µ opioid receptors. When co-administrating of Dezocine with U50,488 H or morphine, Dezocine was capable of inhibiting U50,488H- or morphine-induced antinociception. Finally, κ receptor activation-associated side effect sedation was investigated. We found that Dezocine displayed limited sedative effect with a ceiling effecting at a moderate dose. Thus, our work led to a better understanding of the analgesic mechanism of action of Dezocine in vivo.


Subject(s)
Analgesics, Opioid/pharmacology , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Nociception/drug effects , Receptors, Opioid, kappa/agonists , Receptors, Opioid, mu/agonists , Tetrahydronaphthalenes/pharmacology , Animals , CHO Cells , Cricetulus , Enkephalin, Ala(2)-MePhe(4)-Gly(5)-/pharmacology , Female , Male , Mice , Morphine/pharmacology , Naltrexone/analogs & derivatives , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Pain Measurement , Protein Binding , Signal Transduction/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...